TRDA

4.3506.25%
PS

Peter S. Kim

Director

Dr. Peter S. Kim, Ph.D., has been the President at Merck Frosst Canada Ltd. since January 2003. Dr. Kim has been the Venture Advisor at 5AM Venture Management LLC since 2014. He is a Scientific Co-Founder of Osel Inc. Dr. Kim is Director of Entrada Therapeutics, Inc. since December 2020. Dr. Kim is Virginia & D.K. Ludwig Professor of Biochemistry at Stanford University School of Medicine and is a member of Stanford ChEM-H, a new interdisciplinary Institute at Stanford University. Dr. Kim served as an Executive Vice President of Merck & Co. Inc. from January 2008 to August 1, 2013. He served as the President of Merck Research Laboratories at Merck & Co., Inc. from January 2003 to August 1, 2013. During his tenure, he gained approval of many new medicines and vaccines which includes JANUVIA, GARDASIL, ISENTRESS, ZOSTAVAX, ROTATEQ and VICTRELIS. Dr. Kim served as an Executive Vice President of Research and Development at MRL from 2001 to 2002. He served as an Associate Head of Department of Biology since 1999 to 2001 and Professor of Biology at Massachusetts Institute of Technology (MIT), Investigator of Howard Hughes Medical Institute from 1997 to 2001, Professor of Biology at M.I.T., from 1995 to 2001, Associate Professor of Biology at M.I.T., from 1992 to 1995, Assistant Investigator at Howard Hughes Medical Institute from 1990 to 1993, Assistant Professor of Biology at M.I.T., from 1988 to 1992 and Whitehead Fellow and Whitehead Institute for Biomedical Research from 1985 to 1988. Dr. Kim has been a Member of Board of Directors of Fox Chase Cancer Center since 2003 and Whitehead Institute for Biomedical Research since 2005. He serves as a Member of the Board of Trustees of the Alfred P. Sloan Foundation, the Board of Scientific Governors of The Scripps Research Institute and the Scientific Review Board of the Howard Hughes Medical Institute (HHMI). He has been a Fellow of American Academy of Microbiology since 1997, Fellow of American Association for the Advancement of Science since 1999, Fellow of Biophysical Society since 1999. He served as a Member of Council, Institute of Medicine, National Academy of Sciences, from 2006 to 2008. A structural biologist known for discovering how proteins cause viral membranes to fuse with cells, he has designed compounds that stop membrane fusion by the AIDS virus and has pioneered efforts to develop an HIV vaccine based on similar principles. Dr. Kim received National Academy of Sciences Award in Molecular Biology in 1993, Eli Lilly Award in Biological Chemistry in 1994, Dupont Merck Young Investigator Award in 1994, Pfizer Animal Health Award in 1995, Ho-Am Prize for Basic Science, Samsung Foundation in 1998, Hans Neurath Award, Protein Society in 1999 and Harvey Lecture, The Harvey Society in 2002. He serves as Member of Scientific Advisory Board at Soteria Biotherapeutics, Inc. Dr. Kim holds Ph.D., in Biochemistry from Stanford University in 1985 and A.B. in Chemistry from Cornell University in 1979.

公司職務